Press releases

New coronary stent features thin struts designed for more uniform drug delivery

TAXUS Liberte drug eluting stent, launched in Europe and other international markets in 2005, to launch in U.S. next month

Company will also present results from the ARRIVE diabetic subset analysis, the ATLAS Workhorse and Direct Stenting trials and ATLAS data on small vessels and long lesions

The recent turmoil in the financial markets and bankruptcy of Lehman Brothers triggered automatic share selling

Company to discuss these and other issues on its third quarter earnings call on October 23 at 8:00 a.m.

PERSEUS clinical program to evaluate TAXUS® Element™ Platinum Chromium Stent

Judgment against Company entered in a patent case filed in 1997; Company to appeal

Company also announces FDA approval of TAXUS® Express2™ Stent System for treatment of in-stent restenosis

A live webcast and replay of the September 25 session will be available

Boston Scientific Corporation (NYSE: BSX) announced today a decision by the United States District Court in Delaware. The case involves a patent...

A live webcast and replay of the Tuesday, September 16 session will be available

Company announced positive one-year results from the world's largest post-approval, prospective registry for a single drug-eluting stent (DES)

Overall results demonstrated no statistically significant differences between PCI and CABG in rates of death or myocardial infarction (MI)

Boston Scientific obligation reduced from $250 to $19 million; Company to appeal remaining award

Company to present data from landmark SYNTAX clinical trial

"We were pleased with the quarter, especially with our expense management and working capital initiatives,” said CEO Jim Tobin.

Boston Scientific only company to offer choice of two distinct drugs on separate drug-eluting stent platforms

A live webcast and replay of the July 22 conference call will be available

Legislation would help service veterans and the active armed forces better manage the challenges of chronic pain

Transactions further Company's plans to focus on core businesses and increase shareholder value

Fitch also reaffirmed the Company's long-term credit rating of BB+

A live webcast and replay of the June 11 session will be available

Company announces management changes and further organizational consolidation

Environmentally focused improvements are hallmark of renovations to Endosurgery headquarters

Transaction follows the definitive agreement announced on April 16

Boston Scientific defenses in patent infringement case to be heard by the U.S. District Court in Marshall, Texas on July 31.

Positive results presented at Digestive Disease Week 2008

New size allows for treatment of smaller-diameter diseased saphenous vein grafts

ACUITY® Spiral lead has smallest left ventricular lead tip profile in the industry

Results of international, multi-center registry to be presented at conference

ALTITUDE clinical science initiative will provide insights to ICD and CRT-D device therapy

COGNIS™ CRT-D and TELIGEN™ ICD represent entirely new platforms

Provides valuable insights for diabetic patients, who are often at higher risk for adverse events and repeat stenting procedures

Boston Scientific welcomed two-year results from the SPIRIT III clinical trial, presented at the 2008 EuroPCR Scientific Program in Barcelona.

Company supports efforts of International Diabetes Federation to promote worldwide diabetes care and prevention

"We are very pleased with the decision by the Canadian Federal Court dismissing this case," said Boston Scientific's Chief Operating Officer.

ALTRUA™ is Company's most advanced pacemaker and delivers enhanced therapies while maintaining its small size and battery longevity.

Boston Scientific Corporation (NYSE: BSX) today announced CE Mark approval and market launch of its ALTRUA™ family of pacemakers. ALTRUA is Boston...

Ruling from World Intellectual Property Organization (WIPO) arbitration panel finds no infringement

A live webcast and replay of the May 6 conference session will be available

A live webcast and replay of the April 30 session will be available.

MADIT-CRT trial designed to test whether CRT-Ds can slow the progression of heart failure in heart attack survivors

Award recognizes Boston Scientific's successful use of electronic transactions to improve supply chain efficiency for customers and suppliers

"We continued to make good progress during the quarter, particularly in our efforts to bring expenses in line with revenues," said CEO Jim Tobin.

Company plans to launch product immediately

Acquisition follows a 2007 development agreement to pursue therapeutic solutions for atrial fibrillation, or "Afib"

Emerging technology will potentially enable access to MRI exams for implantable cardiac device patients

ACUITY® Steerable lead also receives reimbursement approval; Company plans to launch product immediately

A live webcast and replay of the April 22 conference call will be available.

Nationally known attorney specializing in medical device and pharmaceutical litigation; will serve on the Company's Executive Committee